Jeffrey Moore
President & Board Member @ MP Healthcare Venture Management
Boston, United States
Jeffrey Moore is a seed investor at MP Healthcare Venture Management in Boston focused on Biotechnology and Medical. President & Board Member at MP Healthcare Venture Management.
- Total investments:
- 6
- Last investment:
- Lead investor:
- 33%
Last updated:
For AI agents: llms.txt
Industries Jeffrey Moore invests in
Stages Jeffrey Moore invests in
Countries Jeffrey Moore invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Biotechnology 4 (67%)
- Medical 3 (50%)
- Therapeutics 3 (50%)
- Health Care 2 (33%)
- Life Science 1 (17%)
Stage
- Seed 4 (67%)
- Series B 1 (17%)
Country
- United States 2 (33%)
- United Kingdom 2 (33%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
TRIMTECH Therapeutics
|
TRIMTECH Therapeutics is a biotech organization that treats neurodegenerative illnesses by using targeted protein degradation (TPD). | $14M / Seed / Jun 23, 2026 | |
|
TRIMTECH Therapeutics
|
TRIMTECH Therapeutics is a biotech organization that treats neurodegenerative illnesses by using targeted protein degradation (TPD). | $31M / Seed / Mar 05, 2025 | |
Outrun TX
|
Outrun TX develops a platform for the identification of therapeutics that selectively target the protein degradation pathway. | $10M / Seed / Apr 18, 2024 | |
PharmEnable
|
PharmEnable has developed a rapid and cost effective way to identify better chemical starting points to drive the discovery of vital new medicines. | $7.5M / Seed / May 22, 2023 | |
QurAlis
|
QurAlis is a operator of a biotechnology company intended to discover and develop potential precision therapeutics for amyotrophic lateral sclerosis (ALS). The company focuses on the link between genetics and disease in ALS and other neurological diseases, enabling doctors to successfully treat ALS . | $88M / Series B / Mar 09, 2023 | |
|
QurAlis
|
QurAlis is a operator of a biotechnology company intended to discover and develop potential precision therapeutics for amyotrophic lateral sclerosis (ALS). The company focuses on the link between genetics and disease in ALS and other neurological diseases, enabling doctors to successfully treat ALS . | $5.5M / Seed / Nov 19, 2018 |
Co-Investors
MPH is the venture capital arm of Mitsubishi Tanabe Pharma Corporation (MTPC). MPH invests in innovative companies developing novel therapeutics, platform technologies, and vaccines.
MP Healthcare Venture Management Contacts
| Name | Phone | Socials | |
|---|---|---|---|
|
Jeffrey Moore
President & Board Member
|
|||
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
FAQ
What does Jeffrey Moore invest in?
Jeffrey Moore invests primarily in Biotechnology, Medical and Therapeutics startups, most often at Seed and Series B stage. Most of the 6 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Jeffrey Moore?
Public channels for Jeffrey Moore include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Jeffrey Moore last invest?
The most recent investment recorded for Jeffrey Moore closed in Jun 2026. Shizune tracks 6 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
